Loading…
Biodexa Pharmaceuticals Plc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in BDRX.
▼ -100.0% over 5Y.
today you would have $0.00▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $11.35 | $202.50 | $3,350.00 | $394,000.00 | |
| P/S | — | — | — | 10459541.7x | 3053436.3x |
| P/B | 449828.0x | 224728.8x | 162689.1x | 851878.0x | 674927.2x |
| EPS | -$0.50 | -$500.00 | -$10,000.00 | -$775,000.00 | |
| Profit margin | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BJDXBluejay Diagnostics, Inc. | $0.90 | — | 0.2x | — | -98.89% | $931.24K |
| NIVFNewGenIvf Group Ltd | $0.34 | 0.0x | 0.0x | — | 79.40% | $833.53K |
| PFSAProfusa, Inc. | $1.69 | — | — | — | — | $1.02M |
| VTAKCatheter Precision, Inc. | $0.20 |
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Company description provided by Yahoo Finance.
| — |
| — |
| -1858.01% |
| -1095.28% |
| ROE | -110.08% | -55.98% | -68.84% | -151.33% | -242.10% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.0x |
| — |
| -111.35% |
| $724.42K |
| CDTCDT Equity Inc. | $1.69 | — | 0.0x | — | -69.68% | $1.33M |
| SXTCChina SXT Pharmaceuticals, Inc. | $3.00 | — | 0.1x | — | -27.49% | $1.6M |